SCHEMBL2568176

SCHEMBL2568176

Cc1[nH]n(-c2ccc(S(=O)(=O)N3CCOCC3)cn2)c(=O)c1Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
GAA P10253 5/20 0.52
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
TSHR P16473 3/20 0.46
NOX4 Q9NPH5 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44
ALKBH3 Q96Q83 1/20 0.42
KAT8 Q9H7Z6 1/20 0.42
LMNA P02545 3/20 0.42
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15258785 0.91 KDM4E (0.58) KDM4EGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL2565000 0.90 KDM4E (0.57) KDM4EGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL15643049 0.82 KDM4E (0.49) KDM4EGAAALDH1A1NOX4MEN1
Hydrochloric Acid SCHEMBL15258808 0.81 KDM4E (0.48) KDM4EGAAALDH1A1NOX4MEN1
SCHEMBL15258757 0.81 L3MBTL1 (0.49) KDM4EGAAALDH1A1TSHRNOX4
SCHEMBL15258875 0.81 LMNA (0.50) KDM4EGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL15258799 0.80 NOX4 (0.55) KDM4EALDH1A1SMN1; SMN2NOX4MEN1
SCHEMBL15258870 0.79 KMT2A (0.45) KDM4EGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL15258732 0.78 SMN1; SMN2 (0.54) KDM4EGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL2571646 0.78 NOX4 (0.54) KDM4EGAAALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382205-B1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI SA (FR) 2014-04-23 EP claimed
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-12-01 US claimed
EP-2382205-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-11-02 EP claimed
WO-2010076524-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI-AVENTIS (FR) 2010-07-08 WO claimed
EP-2382205-B1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI SA (FR) 2014-04-23 EP disclosed
US-8541455-B2 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators SANOFI (FR) 2013-09-24 US disclosed
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS HIF1AN, HIF1A, EGLN2 KDM4E 1006/4885GAA 2546/4885ALDH1A1 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.